🇺🇸 Methyloprednisolone in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 12

Most-reported reactions

1. Drug Interaction — 2 reports (16.67%)
2. Drug Level Decreased — 2 reports (16.67%)
3. Aspergilloma — 1 report (8.33%)
4. Cataract — 1 report (8.33%)
5. Chronic Sinusitis — 1 report (8.33%)
6. Dyspnoea — 1 report (8.33%)
7. Epilepsy — 1 report (8.33%)
8. Graft Versus Host Disease — 1 report (8.33%)
9. Hypercapnia — 1 report (8.33%)
10. Infection — 1 report (8.33%)

Source database →

Frequently asked questions

Is Methyloprednisolone approved in United States?

Methyloprednisolone does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Methyloprednisolone in United States?

Genentech, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.